References
- Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9
- Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
- Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin 2005;21:1741-54
- Rutgeerts PJ. An historical overview of the treatment of Crohn’s disease: why do we need biological therapies? Rev Gastroenterol Disord 2004;4(Suppl 3):S3-9
- Girardin M, Manz M, Manser C, et al. First-line therapies in inflammatory bowel disease. Digestion 2012;86(Suppl 1):6-10
- Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8
- Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:617-29
- Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24
- Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-83, quiz 4, 84
- Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842-5
- Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003;4:CD000301
- Bultman E, Kuipers EJ, van der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:313-23
- Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2013;4:CD000545
- Hanauer SB, Kamm MA, Colombel JF. Sustained steroid-free clinical remission in patients with moderate to severe Crohn’s disease treated with adalimumab [abstract 1181]. Am J Gastroenterol 2006;101:S460
- Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61
- Sandborn WJ, Feagan BG, Lee SD, et al. Baseline corticosteroid-free clinical remission in Crohn’s disease patients treated with certolizumab pegol in the PRECiSE 2 trial [abstract P-25]. Inflamm Bowel Dis 2012;18(Suppl 1):S23-4
- McDonald JW, Tsoulis DJ, Macdonald JK, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2012;12:CD003459
- Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn’s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis 2013;19:1173-8
- Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol 2002;97:803-23
- Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
- Feagan BG, Lémann M, Befrits R, et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012;18:152-60
- Colombel JF, Louis E, Peyrin-Biroulet L, et al. Deep remission: a new concept? Dig Dis 2012;30(Suppl 3):107-11
- Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97